Company Filing History:
24 out of 525 
1 out of 1 Years Active: 1994-2013
Title: The Innovations of Etienne De Plaen in Cancer Research
Introduction
Etienne De Plaen is a prominent figure in the field of cancer research, residing in Brussels, Belgium. With an impressive portfolio of 25 patents, De Plaen has contributed significantly to the development of innovative therapeutic strategies targeting tumor rejection antigens.
Latest Patents
Among his latest innovations is a patent focusing on tumor rejection antigens, specifically polypeptides that can complex with major histocompatibility complex molecules, particularly HLA-A2.1. This innovation aims to enhance the immune response against cancer cells. Another notable patent pertains to isolated tumor rejection antigen precursor proteins, MAGE-2 and MAGE-3, which involves an isolated DNA sequence coding for an antigen expressed by tumor cells, recognized by cytotoxic T cells. This recognition is vital as it leads to the lysis of tumor cells expressing these antigens. The patent also encompasses cells transfected by this DNA sequence and highlights various therapeutic and diagnostic applications resulting from the properties of the DNA and antigen.
Career Highlights
De Plaen has had a distinguished career, working with esteemed organizations such as the Ludwig Institute for Cancer Research Limited and the Ludwig Institute. His work in these institutions has propelled advancements in understanding how the immune system can be harnessed to combat cancer.
Collaborations
Throughout his career, De Plaen has collaborated with several notable professionals, including Thierry R. Boon-Falleur and Catia Traversari. These collaborations have enriched his research endeavors and have played a pivotal role in the innovation of new cancer therapies.
Conclusion
Etienne De Plaen continues to be a leading innovator in cancer research, with his patents reflecting his significant contributions to the field. His work not only advances scientific understanding but also opens new avenues for potential treatments, underscoring his role as a key inventor in the ongoing battle against cancer.